-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Immune checkpoint inhibitors (ICIS) block inhibitory T cell receptors and promote enhanced anti-tumor activity
.
These drugs, especially antibodies against CTLA-4, PD-1 and PD-L1 , have changed cancer treatments and have been approved for 15 different cancers
, Has changed the method of cancer treatment, and has been approved for 15 different cancers
In this retrospective cohort study, patients with previous psoriasis from 8 academic centers were evaluated and these patients received ICI for cancer
In this multicenter study, ICI treatment was associated with frequent exacerbations of psoriasis, and the onset of psoriasis could be controlled by standard psoriasis treatment, and ICI was rarely discontinued
.
Therefore, patients with a history of psoriasis can receive ICI for malignant tumors
Patients with a history of psoriasis can receive ICI for malignant tumors
Literature source: Halle BR, Betof Warner A, Zaman FY, Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy.
Leave a message here